首页> 外文期刊>HEC forum: an interdisciplinary journal on hospitals’ ethical and legal issues >Barriers to Effective Deliberation in Clinical Research Oversight
【24h】

Barriers to Effective Deliberation in Clinical Research Oversight

机译:临床研究监督有效审议的障碍

获取原文
获取原文并翻译 | 示例
           

摘要

Ethical oversight of clinical research is one of the primary means of ensuring that human subjects are protected from the natural bias of researchers and research institutions in favor of experimentation. At a minimum, effective oversight should ensure that risks are minimized and reasonable in relation to anticipated benefits, protect vulnerable subjects from potential coercion or undue influence, ensure full and informed consent, and promote the equitable distribution of the risks and benefits of research. Because these assessments often involve value judgments for which there are no agreed-upon objective standards, we rely on deliberative procedures thought to have the greatest likelihood of producing the right or best outcomes. Concerns about the potential for improperly functioning IRBs to waste scarce human and institutional resources and impede biomedical progress have motivated a surge in empirical research assessing their procedures and outcomes. Yet within this literature, there has been minimal attention paid to the social scientific evidence regarding how individuals and deliberating groups make decisions, nor how those data might inform IRB practice. This essay seeks to fill that gap, locating recent empirical data on IRB composition and process within the context of data regarding what I call "deliberative pathologies," or instances when deliberation fails to live up to one or more aspect of the deliberative ideal because of systematic biases in the ways participants interact. The paper goes on to make evidence-based recommendations to reduce the vulnerability of IRB deliberations to the kinds of pathologies discussed and indicate directions for future research.
机译:临床研究的道德监督是确保人类受试者免受研究人员和研究机构的自然偏见,支持实验的主要方法之一。至少有效监督应确保风险最小化,与预期的福利有关,保护弱势受试者免受潜在的胁迫或过度影响,确保全面知识同意,并促进了研究的风险和利益的公平分配。由于这些评估往往涉及没有商定的客观标准的价值判断,我们依靠审议程序认为具有产生权利或最佳成果的最大可能性。对不正当运作的IRB浪费缺乏人类和体制资源的担忧,并且阻碍了生物医学进展的促使在实证研究中飙升,评估其程序和结果。然而,在这篇文章中,对个人和审议团体如何做出决定的社会科学证据,也是最小的关注,也不是那些数据如何通知IRB实践。本文旨在填补这种差距,在数据上找到关于IRB组成和进程的最新实证数据,以及在审议失败时,在审议失败时,审议失败时的情况参与者互动的方式系统偏见。本文继续做出基于证据的建议,以减少IRB审议对讨论的种类的脆弱性,并表明未来研究的指示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号